Ramon Yitzchak, Barak Yoreh, Ullmann Yehuda, Hoffer Erica, Yarhi Danielle, Bentur Yedidia
Department of Plastic and Reconstructive Surgery, Rambam Health Care Campus, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Israel.
Ther Drug Monit. 2007 Oct;29(5):644-7. doi: 10.1097/FTD.0b013e3180eaa10a.
The maximal recommended local anesthetic dose of lidocaine is 7 mg/kg; higher doses are used in tumescent liposuction. The objective of this study was to characterize the pharmacokinetics of high-dose diluted lidocaine administered together with epinephrine for local anesthesia in facelift procedures. This was a prospective study of six female patients undergoing elective facelift surgery. The local anesthetic solution consisted of 0.33% lidocaine, 0.07% sodium bicarbonate, and 1:600,000 epinephrine in normal saline. Plasma lidocaine levels were determined in the course of 24 hours and were subjected to pharmacokinetic analysis. Patients' age was 58.5 +/- 8 years and weight 68.5 +/- 18.7 kg. Mean lidocaine dose was 21.6 +/- 3.6 mg/kg (range, 17.5-26.3 mg/kg) infiltrated subcutaneously over 20 minutes or less. No lidocaine-related adverse effects were recorded. Major bleeding was not observed. Postoperative analgesia was required only at 11.8 +/- 4.6 hours after surgery. Pharmacokinetic analysis was peak concentration 1.41 +/- 0.4 microg/mL, time to reach peak concentration 9.3 +/- 1.6 hours, terminal half-life 6.2 +/- 1.5 hours, area under the curve from time zero to last data point 1379.8 +/- 470 microg/min/mL, and area under the curve from time zero to infinity 1530.6 +/- 471.6 microg/min/mL. Plasma lidocaine concentrations formed almost a plateau between 2 and 12 hours (ie, at approximately 1.2 microg/mL) after infiltration. It is concluded that local anesthesia with diluted lidocaine at a dose 3.1 times higher than the currently recommended dose (7 mg/kg) administered with epinephrine yielded a peak plasma lidocaine level that was 72% below the level considered safe (5 microg/mL).
利多卡因的最大推荐局部麻醉剂量为7毫克/千克;在肿胀吸脂术中使用的剂量更高。本研究的目的是描述在面部提升手术中高剂量稀释利多卡因与肾上腺素联合用于局部麻醉时的药代动力学特征。这是一项对6名接受择期面部提升手术的女性患者进行的前瞻性研究。局部麻醉溶液由0.33%利多卡因、0.07%碳酸氢钠和1:600,000肾上腺素溶于生理盐水中组成。在24小时内测定血浆利多卡因水平,并进行药代动力学分析。患者年龄为58.5±8岁,体重为68.5±18.7千克。平均利多卡因剂量为21.6±3.6毫克/千克(范围为17.5 - 26.3毫克/千克),在20分钟或更短时间内皮下浸润。未记录到与利多卡因相关的不良反应。未观察到大出血情况。仅在术后11.8±4.6小时需要术后镇痛。药代动力学分析结果为:峰浓度1.41±0.4微克/毫升,达峰时间9.3±1.6小时,终末半衰期6.2±1.5小时,从零时间到最后一个数据点的曲线下面积1379.8±470微克/分钟/毫升,从零时间到无穷大的曲线下面积1530.6±471.6微克/分钟/毫升。浸润后,血浆利多卡因浓度在2至12小时之间几乎形成一个平台期(即约为1.2微克/毫升)。结论是,用比当前推荐剂量(7毫克/千克)高3.1倍的稀释利多卡因与肾上腺素联合进行局部麻醉时,血浆利多卡因峰水平比认为安全的水平(5微克/毫升)低72%。